APCS iRNA Compositions for Targeted SAP mRNA Cleavage

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is no effective cure for amyloidosis and other diseases associated with serum amyloid P component (SAP), which contribute to tissue damage and organ dysfunction by stabilizing protein aggregates and inhibiting fibril removal.

Innovation Solution

Development of iRNA compositions that target and cleave APCS gene transcripts, using double-stranded RNAi agents to selectively inhibit SAP expression, thereby reducing amyloid deposit formation and associated symptoms.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Stability of the object's composition

If SAP is used to stabilize protein aggregates, then amyloid deposit formation is enhanced, but tissue damage and organ dysfunction increase

Engineering Contradiction:

Improveamyloid deposit stabilityVSAvoidtissue damage

Core Design Contradiction:

Stability of the object's compositionVSObject-affected harmful factors

Solution Approach 1:

The patent converts the harmful stabilizing function of SAP into a beneficial target for therapeutic intervention. By designing iRNA compositions that specifically target and degrade SAP mRNA, the invention eliminates the harmful amyloid-stabilizing activity while maintaining the specificity needed to avoid off-target effects. This transforms the previously harmful protein function into a可控 therapeutic target.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The invention extracts and removes SAP from the pathological system by using iRNA to specifically degrade SAP mRNA before it can be translated into protein. This extraction approach selectively eliminates the harmful component (SAP) from the amyloid deposit formation process without affecting other necessary biological functions.

Inventive Principle:

Principle #2Taking out (Extraction)

2Reliability

If no effective cure exists for amyloidosis, then patient survival is limited, but treatment options remain insufficient

Engineering Contradiction:

Improvedisease treatment efficacyVSAvoidtreatment availability

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent changes the fundamental parameter of SAP expression levels by introducing iRNA therapy. By controlling the amount and activity of administered iRNA compositions, the treatment can modulate SAP mRNA degradation to achieve therapeutic reduction of amyloid deposits while maintaining safety margins. This parameter control enables effective treatment where none previously existed.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention introduces iRNA compositions as an intermediary therapeutic agent that mediates between the administered treatment and the pathological SAP protein. The iRNA acts as a molecular mediator that specifically binds and degrades SAP mRNA, providing a controlled mechanism to reduce amyloid formation without directly interacting with the complex amyloid deposits themselves.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Productivity

If SAP inhibits fibril removal through scavenging mechanisms, then amyloid clearance is reduced, but protein aggregate accumulation increases

Engineering Contradiction:

Improvefibril removal rateVSAvoidamyloid load

Core Design Contradiction:

ProductivityVSQuantity of substance

Solution Approach 1:

The patent applies preliminary action by degrading SAP mRNA before it can be translated into functional SAP protein that would inhibit fibril clearance. By preventing SAP protein synthesis through mRNA degradation, the treatment removes the inhibitory barrier to natural fibril removal mechanisms before the problem of amyloid accumulation can worsen.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The invention applies preliminary anti-action by using iRNA to counteract and neutralize the harmful inhibitory effect of SAP on fibril removal. The iRNA composition acts in advance to block SAP mRNA translation, thereby preventing the protein from exerting its harmful scavenging activity that would otherwise reduce amyloid clearance rates.

Inventive Principle:

Principle #9Preliminary anti-action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The iRNA compositions effectively reduce SAP expression, leading to decreased amyloid load and symptom amelioration in subjects with amyloidosis and related diseases, providing a therapeutic approach to manage these conditions.

Implementation Method 1

double stranded ribonucleic acid (RNAi) agent for inhibiting expression of a serum amyloid P component (APCS) gene, comprising a sense strand and an antisense strand

Methodology Applied

Scientific EffectBase pairing:

Implementation Method 2

effect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of an APCS gene

Methodology Applied

Scientific EffectRNA cleavage:

Data Source

PatentUS20250276001A1SERUM AMYLOID P COMPONENT (APCS) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

Publication Date: 2025.09.04 ALNYLAM PHARMACEUTICALS INC

AI summary

The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the serum amyloid P component (APCS) gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of an APCS gene and to treat subjects having an APCS-associated disease, e.g., amyloidosis, Alzheimer's disease or coronary atherosclerotic heart disease.